Dr. Choueiri on Significance of CheckMate-025 Study for RCC
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 for renal cell carcinoma.
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 study in renal cell carcinoma (RCC).
The phase III study compared the efficacy of everolimus, the standard of care, versus nivolumab in patients with metastatic RCC who had received at least one VEGF inhibitor. Results showed that there was a significant survival benefit with nivolumab versus everolimus This led to the drug’s FDA approval.
In subgroup analyses of the study, it was concluded that nivolumab demonstrated improved survival over everolimus in all subgroups, including in poor-risk patients.
<<<
